China SXT Pharmaceuticals: Orca reports 9.9% stake

Warrant exercise is constrained by a 9.99% beneficial-ownership cap, while the percentage calculation excludes shares underlying both warrant classes.

Rhea-AI Filing Summary

China SXT Pharmaceuticals, Inc. (SXTC) is the issuer for which Orca Capital reported beneficial ownership of 1,112,788 Class A ordinary shares, or 9.9% of the class. Orca Capital reported sole voting and dispositive power over 1,112,788 shares and zero shared voting or dispositive power. Its ownership-percentage calculation used 10,357,498 Class A ordinary shares outstanding immediately after giving effect to completion of the registered offering, and excluded 887,212 shares issuable under pre-funded warrants and 2,000,000 issuable under common warrants. The warrant terms include a 9.99% blocker on exercises that would cause ownership to exceed that level. The statement was signed by Thomas Konig, listed with the title Director.

Key Figures

Beneficial ownership: 1,112,788 shares Percent of class: 9.9% Shares outstanding: 10,357,498 shares +3 more

6 metrics

Beneficial ownership 1,112,788 shares Orca Capital's reported amount

Percent of class 9.9% Orca Capital's reported beneficial ownership

Shares outstanding 10,357,498 shares Immediately after giving effect to completion of the registered offering; basis stated for ownership percentages

Shares issuable under pre-funded warrants 887,212 shares Excluded from the ownership-percentage calculation

Shares issuable under common warrants 2,000,000 shares Excluded from the ownership-percentage calculation

Warrant exercise blocker 9.99% Exercise is limited if it would result in beneficial ownership above this percentage

Key Terms

beneficially owned, Sole Voting Power, Sole Dispositive Power, pre-funded warrants, +1 more

5 terms

beneficially owned regulatory

"Amount beneficially owned"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power regulatory

"Sole Voting Power 1,112,788.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power regulatory

"Sole Dispositive Power 1,112,788.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

pre-funded warrants financial

"shares issuable upon the exercise of pre-funded warrants"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

9.99% Blocker regulatory

"the "9.99% Blocker""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SXTC shares does Orca Capital beneficially own?

Orca Capital reported beneficial ownership of 1,112,788 China SXT Pharmaceuticals Class A ordinary shares, or 9.9% of the class. It reported sole voting and dispositive power over 1,112,788 shares and no shared voting or dispositive power.

What warrant limits apply to Orca Capital's SXTC ownership?

The warrant terms bar exercises that would cause Orca Capital's beneficial ownership to exceed 9.99% of outstanding Class A ordinary shares. The ownership-percentage calculation excluded 887,212 shares issuable upon exercise of pre-funded warrants and 2,000,000 shares issuable upon exercise of common warrants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/15/2026 - 05:00 PM EDT Accepted by SEC EDGAR 10/15/2026 - 05:00 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

China SXT Pharmaceuticals, Inc.

(Name of Issuer)

Class A Ordinary Shares, no par value

(Title of Class of Securities)

G2161P157

(CUSIP Number)

10/08/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): G2161P157

1

Names of Reporting Persons

Orca Capital AG

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

GERMANY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,112,788.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,112,788.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,112,788.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: All ownership percentages set forth in this Schedule 13G are calculated based upon an aggregate of 10,357,498 Class A ordinary shares outstanding immediately after giving effect to the completion of the Issuer's registered offering as provided in the Issuer's Prospectus Supplement filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on October 9, 2026, and excludes 887,212 Class A ordinary shares issuable upon the exercise of pre-funded warrants and 2,000,000 Class A ordinary shares issuable upon the exercise of common warrants, subject to the 9.99% Blocker (defined below). Pursuant to the terms of the pre-funded warrants and the common warrants, the Reporting Person cannot exercise any of the warrants to the extent the Reporting Person would beneficially own, after any such exercise, more than 9.99% of the Issuer's outstanding Class A ordinary shares (the "9.99% Blocker").

SCHEDULE 13G

Item 1.
(a)	Name of issuer: China SXT Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 178 Taidong Rd North, Taizhou, Jiangsu, China
Item 2.
(a)	Name of person filing: Orca Capital AG
(b)	Address or principal business office or, if none, residence: Sperlring 2 85276 Hettenshausen Deutschland
(c)	Citizenship: Germany
(d)	Title of class of securities: Class A Ordinary Shares, no par value
(e)	CUSIP Number(s): G2161P157
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,112,788
(b)	Percent of class: 9.9 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,112,788
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,112,788
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Orca Capital AG

Signature:	/s/ Thomas Konig
Name/Title:	Thomas Konig/Director
Date:	10/15/2026